Adding Merck/Moderna’s individualized mRNA therapy intismeran to pembrolizumab cut the risk of recurrence or death by 42% in resected stage IIB-IV melanoma, per full phase 3 INTerpath-001 results. 2-yr RFS: 82.2% vs 70.0%. #ESMO2026 https://t.co/UlR637ltce https://t.co/BlGocP08FM